logo-loader

Orgenesis teams up with European firm Educell on T-cell research projects

Published: 08:45 14 Jul 2020 EDT

Cancer cell
The first collaboration will focus on the development of CAR-T and whole-cell-based vaccine platform for use in cancer immunotherapies

Orgenesis Inc (NASDAQ:ORGS) has reached a collaboration deal to conduct cell-based research projects with European cell therapy company Educell Ltd, the company announced Tuesday. 

The two companies will utilize the Orgenesis Cell and Gene Therapy (CGT) Biotech Platform, which includes the company’s point of care (POCare) network and associated technologies. Orgenesis’ POC Network includes leading hospitals and research institutes around the world, the company said.

The first collaboration will focus on the development of CAR-T and whole-cell-based vaccine platform for use in cancer immunotherapies. The parties also plan to collaborate with local medical centers.

“This latest collaboration with Educell expands our activities in Europe and we believe that it should help us launch our therapies into additional European hospitals, as well as help Educell commercialize their therapies around the world,” Orgenesis CEO Vered Caplan said in a statement. 

READ: Orgenesis to collaborate with Fortune 500 firm Leidos on potential coronavirus treatment

“We also believe that this collaboration reinforces the significant value proposition and flexibility of our CGT Biotech Platform,” Caplain added. “We look forward to benefiting from the expertise of Educell as we seek to expand our automated T-cell culturing approach into clinical validation and commercialization phases.”

Educell is currently preparing cell therapy products for the treatment of articular cartilage, vesicoureteral reflux, regeneration of bone tissue and treatment of immunological disorders, which are in use at the University Medical Centre Ljubljana and other institutions in Slovenia.

“We are excited to team with Orgenesis to potentially advance these breakthrough therapies into clinical trials using cutting edge technologies,” Educell CEO Miomir Knežević said. “This collaboration reflects our commitment to bringing new, effective and affordable cell and gene therapy products to cancer patients worldwide while highlighting Educell’s ability to ensure safety in the process and help to reduce overall manufacturing costs.”

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

5 hours, 57 minutes ago